A Study for Patients With Secondary Progressive Multiple Sclerosis

Inclusion Criteria: * Documented history of SPMS * Absence of relapse in the 3mos prior to baseline * EDSS of 3.5 - 6.5 * Pyramidal or Cerebellar FSS greater than or equal to 3 * A cohort of 100 HLA DR2/4 negative patients is required. Once enrollment to this cohort is complete, all further patients are required to be HLA DR2/4 positive. * Informed consent * Subject reliability and compliance Exclusion Criteria: * Diagnosis of Primary Progressive MS * Subjects have previously received MBP8298 * Recent history of malignancy, with the exclusion on basal cell carcinoma. * Steroid therapy within 30 days prior to first study specific procedure or any other treatment known to be used for putative or experimental MS treatment * Therapy with beta-interferon, glatiramer acetate within 3 mos or mitoxantrone, cyclophosphamide, methotrexate, azathioprine, or any other immuno-modulating or immunosuppressive drugs including recombinant or non-recombinant cytokines or plasma exchange within 6 mos prior to performance of the first study-specific test, with the exception of corticosteroids or ACTH for relapse treatment. * Initiation or discontinuation of therapy with 4-AP or 3,4-DAP at any time during the study period. * History of anaphylactic/anaphlactoid reactions to glatiramer acetate * Abnormal lab values at the Screening Visit deemed by the Investigator to be clinically significant * Known allergy to Gadolinium-DTPA * Treatment at any time with Cladribine, total lymphoid irradiation, monoclonal antibody treatment * Treatment at any time wtih an altered peptide ligand * Any conditions that could interfere with the performance of study specific procedures e.g.MRI * Previous randomization to this study * Known positivity for HIV, Hepatitis B, or Hepatitis C * Participation in any other non-MS clinical trial within 30 days prior to performance of the first study specific test or any investigational therapy in the past 6 mos. * Females who are breast feeding, pregnant or not using a medically approved method of contraception regularly * Known or suspected current or past alcohol or drug abuse (within the last year) * Any medical, psychiatric or other condition that could result in a subject not being able to give fully informed consent, or to comply with the protocol requirements * Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in the study